Page 211 - HIV/AIDS Guidelines

Table 16b. Interactions between Non-Nucleoside Reverse Transcriptase Inhibitors*, Maraviroc,
Raltegravir, and Protease Inhibitors* (Page 1 of 3)

*DLV, IDV, and NFV are not included in this table. Refer to the DLV, IDV, and NFV FDA package inserts for information regarding drug
interactions.

EFV ETR NVP RPV a MVC RAL
With unboosted ATV With unboosted ATV With (ATV 300 mg With boosted With unboosted With unboosted
ATV: AUC ↓ 74% ETR: AUC ↑ 50%, + RTV 100 mg) and unboosted ATV ATV
EFV: no significant C max ↑ 47%, and once daily ATV MVC: AUC ↑ RAL: AUC ↑ 72%
change C min ↑ 58% ATV: AUC ↓ 42% ↑ RPV possible 257%
ATV: AUC ↓ 17% and and C ↓ 72% With (ATV 300
min
With (ATV 300 mg + C ↓ 47% NVP: AUC ↑ 25% With (ATV 300 mg + RTV 100
PK RTV 100 mg) once min mg + RTV 100 mg) once daily
data daily with food With (ATV 300 mg + mg) once daily RAL: AUC ↑ 41%
ATV concentrations RTV 100 mg) once daily MVC: AUC ↑
similar to unboosted ETR: AUC, C max , and 388%
ATV without EFV C min ↑ approximately
ATV 30%
+/- ATV: AUC ↓ 14% and
RTV C min ↓ 38%
Dose Do not coadminister Do not coadminister Do not Standard MVC 150 mg BID Standard
with unboosted ATV. with ATV +/− RTV. coadminister with with ATV +/− RTV
ATV +/− RTV.
In ART-naive patients
(ATV 400 mg +
RTV 100 mg) once
daily
Do not coadminister
in ART-experienced
patients.
With (DRV 300 mg + ETR 100 mg BID with With (DRV 400 mg RPV 150 mg With With
RTV 100 mg) BID (DRV 600 mg + + RTV 100 mg) once daily with (DRV 600 mg + (DRV 600 mg +
DRV: AUC ↓ 13%, RTV 100 mg) BID BID (DRV 800 mg + RTV 100 mg) BID RTV 100 mg)
C min ↓ 31% DRV: no significant DRV: AUC ↑ 24% b RTV 100 mg) MVC: AUC ↑ BID
EFV: AUC ↑ 21% change NVP: AUC ↑ 27% once daily 305% RAL: AUC ↓ 29%
PK ETR: AUC ↓ 37%, and C min ↑ 47% DRV: no and C min ↑ 38%
data C min ↓ 49% significant With
change (DRV 600 mg +
DRV – RPV: AUC ↑ RTV 100 mg) BID
always 130% and + ETR
use C ↑ 178% MVC: AUC ↑
with min 210%
RTV
Clinical significance Standard (ETR 200 mg Standard Standard MVC 150 mg BID Standard
unknown. Use BID)
standard doses and Despite decreased ETR
monitor patient concentration, safety and
Dose
closely. Consider efficacy of this
monitoring drug combination have been
levels. established in a clinical
trial.
↓ ETR possible NVP: no significant ↓ RPV possible MVC: AUC ↓ EFV: AUC ↓ 36%
PK change 45%
data
EFV • EFV: AUC ↓ 22%
Do not coadminister. Do not Do not MVC: 600 mg Standard
Dose
coadminister. coadminister. BID

Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents K-41

Downloaded from http://aidsinfo.nih.gov/guidelines on 12/8/2012 EST.